Table 2.

Baseline patient characteristics (blank cells indicate nonsignificant p-values at 0.05 level).

G3 panNENs	All (n=45)	G3 WD-panNETs (n=16)	PDNEC (n=29)	Significant differences between G3 WD- panNETs and PDNEC
	N (%)	N (%)	N (%)	p-value
Mean age, years	54	47	58	0.016
Range	(26-78)	(26-73)	(32-78)
Sex
Female	19 (42%)	9 (56%)	10 (34%)
Male	26 (58%)	7 (44%)	19 (66%)
Performance Status (ECOG)				0.04
0	6 (13%)	5 (31%)	1 (3%)
1	31 (69%)	10 (63%)	21 (72%)
2	6 (13%)	1 (6%)	5 (17%)
3-4	2 (4%)	0 (0%)	2 (7%)
Smoker/prior smoker	21 (47%)	4 (25%)	17 (59%)	0.0307
History of second malignancy	4 (9%)	1 (6%)	3 (10%)
Symptomatic at presentation	43 (96%)	15 (94%)	28 (97%)
Pain	29 (64%)	10 (63%)	18 (62%)
Weight loss	25 (56%)	5 (31%)	20 (69%)	0.0271
Jaundice	10 (22%)	0 (0%)	10 (34%)	0.0080
Hyperglycemia	3 (7%)	0 (0%)	3 (10%)
Primary tumor location
Uncinate process	2 (4.4%)	2 (13%)	0 (0%)
Head	16 (36%)	3 (19%)	13 (45%)
Body	7(16%)	0 (0%)	6 (21%)
Tail	18 (40%)	11 (69%)	8 (28%)	0.0118
Peripancreatic soft tissue	2 (4.4%)	0 (0%)	2 (7%)
Mean primary tumor size (cm)	4.2	4.3	4.1
Range	(1-13.5)	(1-13.5)	(1.4-9)
Primary tumor resected	8 (18%)	6 (38%)	2 (7%)
Location of metastases at presentation
Liver	39 (87%)	14 (88%)	25 (86%)
Lymph nodes	20 (44%)	4 (25%)	16 (55%)
Lung	1 (2%)	0 (0%)	1 (3%)
Bone	3 (7%)	2 (13%)	1 (3%)
Brain	0 (0%)	0 (0%)	0 (0%)
Ovary	3 (7%)	3 (19%)	0 (0%)	0.0395
Other	3 (7%)	0 (0%)	3 (10%)
Octreoscan positive	19/27 patients tested (70%)	13/15 patients tested (87%)	6/12 patients tested (50%)
Functional	4 (8.9%)	4 (25%)	0 (0%)	0.0122
Insulinoma	1 (2.2%)	1 (6%)
Gastrinoma	3 (6.7%)	3 (19%)
Paraneoplastic syndrome at presentation	1 (2.2%)	0 (0%)	1 (3%)
Histology
Small cell	5 (11%)	0 (0%)	5 (17%)
Large cell	40 (89%)	16 (100%)	24 (83%)
Average Ki-67 proliferation index % (range)		47 (25-80)	73 (20-95)

Abbreviations: G3 panNENs, grade 3 pancreatic neuroendocrine neoplasms; G3 WD-panNETs, grade 3 well differentiated pancreatic neuroendocrine tumors; PDNEC, poorly differentiated neuroendocrine carcinomas.